Non-Hodgkins Lymphomas (cont.)
Jerry R. Balentine, DO, FACEP
Dr. Balentine received his undergraduate degree from McDaniel College in Westminster, Maryland. He attended medical school at the Philadelphia College of Osteopathic Medicine graduating in1983. He completed his internship at St. Joseph's Hospital in Philadelphia and his Emergency Medicine residency at Lincoln Medical and Mental Health Center in the Bronx, where he served as chief resident.
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
In this Article
- Non-Hodgkin's lymphoma facts
- What is non-Hodgkin's lymphoma?
- What is the difference between non-Hodgkin's lymphoma and Hodgkin's disease (or Hodgkin's lymphoma)?
- What causes non-Hodgkin's lymphoma?
- What are non-Hodgkin's lymphoma risk factors?
- What are non-Hodgkin's lymphoma symptoms and signs?
- What kind of doctors treat non-Hodgkin's lymphoma?
- How do physicians diagnose non-Hodgkin's lymphoma?
- What are the types of non-Hodgkin's lymphoma, and how is non-Hodgkin's lymphoma staging determined?
- What is the treatment for non-Hodgkin's lymphoma?
- What is the prognosis and survival rate for non-Hodgkin's lymphoma?
- Is it possible to prevent non-Hodgkin's lymphoma?
- Where can people find more information about non-Hodgkin's lymphoma?
- Find a local Oncologist in your town
What is the prognosis and survival rate for non-Hodgkin's lymphoma?
The prognosis of NHL can be good but is linked to the type of lymphoma, the extent of spread (staging), and response to therapy. Prognosis should be discussed with the patient's health-care provider.
Five-year survival is a measure used to predict and gauge the severity of the cancer. Patients should discuss risk factors, staging, and classifications with their health-care team as none of these numbers should be applied to an individual patient without considering all the circumstances of the patient's illness.
The National Cancer Institute reports the following average five-year survival:
|Stage at diagnosis||Stage distribution (%)||Five-year relative survival (%)|
|Localized (confined to primary site)||28||81.6|
|Regional (spread to regional lymph nodes)||15||72.9|
|Distant (cancer has metastasized)||49||61.6|
Is it possible to prevent non-Hodgkin's lymphoma?
Most people with non-Hodgkin's lymphoma have no risk factors that can be identified. This makes it difficult to prevent the disease.
Most known causes of lymphoma are difficult to avoid, such as medications that suppress the immune system, as they are usually life-saving medications needed for other reasons.
Where can people find more information about non-Hodgkin's lymphoma?
Leukemia & Lymphoma Society
1311 Mamaroneck Avenue, Suite 310
White Plains, NY 10605
United States. National Cancer Institute. "Adult Non-Hodgkin Lymphoma Treatment (PDQ) -- Patient Version." Mar. 3, 2016. <http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>.
Find out what women really need.